文献速递艾滋病与性传播感染

GSK2838232(第二代HIV-1成熟抑制剂)在HIV-1感染者中的安全性、药代动力学和抗病毒活性:IIa期研究

A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 Infection.
PubMed 文献 · Clin Infect Dis · 2020-01-01

该IIa期开放标签、适应性剂量范围研究评估了GSK2838232联合cobicistat在33例HIV-1感染者中的安全性、药代动力学和疗效。受试者每日一次接受20-200mg GSK2838232联合150mg cobicistat治疗10天。结果显示药物安全耐受,暴露量随重复给药增加2-3倍,各剂量组病毒载量均下降,支持其作为联合抗逆转录病毒治疗的一部分继续开发。

要点

  • GSK2838232联合cobicistat在HIV-1感染者中安全耐受,无临床意义的安全性参数或不良事件变化。
  • 重复给药后暴露量(Cmax和AUC0-24)增加2-3倍,呈近似剂量比例关系,第8天达稳态,半衰期为16.3至19.2小时。
  • 20mg、50mg、100mg和200mg剂量组第11天HIV-1 RNA较基线平均最大降幅分别为-0.67、-1.56、-1.32和-1.70 log10 copies/mL。

核心结论

  • GSK2838232联合cobicistat耐受良好,作为短期单药治疗在HIV-1感染者中显示出疗效,支持其作为联合抗逆转录病毒治疗的一部分继续开发。

研究设计与样本

  • IIa期开放标签、适应性剂量范围概念验证研究,纳入33例HIV-1感染者,每日一次接受GSK2838232(20-200mg)联合cobicistat 150mg治疗10天。

主要发现

  • 未观察到临床意义的安全性参数变化或不良事件。
  • 重复给药后暴露量(Cmax和AUC0-24)增加2-3倍,呈近似剂量比例关系,第8天达稳态,半衰期16.3至19.2小时,清除率和半衰期不依赖剂量。
  • 所有剂量组病毒载量均较基线下降,20mg、50mg、100mg和200mg组第11天HIV-1 RNA平均最大降幅分别为-0.67、-1.56、-1.32和-1.70 log10 copies/mL。
  • CD4+细胞计数在≥50mg剂量组增加。

临床怎么用

  • GSK2838232为口服第二代HIV-1成熟抑制剂,需联合药代动力学增强剂cobicistat使用,每日一次给药。
  • 当前证据仅支持其作为短期单药治疗的疗效,临床需作为联合抗逆转录病毒治疗的一部分继续研究。

局限性

  • 研究为开放标签设计,样本量较小(N=33),治疗时间仅10天,为短期单药治疗的概念验证研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: GSK2838232 is a second-generation, potent, small-molecule, oral human immunodeficiency virus type 1 (HIV-1) maturation inhibitor for once-daily administration boosted with a pharmacoenhancer. METHODS: The phase 2a, proof-of-concept study was an open-label, adaptive dose-ranging design. Safety, pharmacokinetics, and efficacy of GSK2838232 boosted by cobicistat were evaluated in individuals with HIV-1 infection. The study participants (N = 33) received GSK2838232 once daily across a range of doses (20-200 mg) with cobicistat 150 mg for 10 days. RESULTS: GSK2838232 was safe and well tolerated with no clinically meaningful changes in safety parameters or adverse events. Exposure (maximum concentration and area under the concentration-time curve from time zero to the concentration at 24 hours postdose) increased 2- to 3-fold with repeated dosing in an approximately dose-proportional manner, reaching steady-state by day 8 with a half-life (t½) from 16.3 to 19.2 hours. Clearance and t½ values were not dependent on dose. Viral load declined from baseline with all GSK2838232 doses. Mean maximum declines from baseline to day 11 in HIV-1 RNA log10 copies/mL with the 20-mg, 50-mg, 100-mg, and 200-mg cohorts were -0.67, -1.56, -1.32, and -1.70, respectively. CD4+ cell counts increased at doses ≥50 mg. CONCLUSIONS: GSK2838232 with cobicistat was well tolerated and exhibited efficacy as a short-term monotherapy in participants with HIV-1. This positive proof-of-concept study supports the continued development of GSK2838232 for the treatment of HIV as part of combination antiretroviral therapy. CLINICAL TRIALS REGISTRATION: NCT03045861.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. DeJesus E, Harward S, Jewell RC, et al. A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 Infection. Clin Infect Dis. 2020. PMID: 31769793. doi:10.1093/cid/ciz938

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。